Skip to main content
Erschienen in: Indian Journal of Gastroenterology 3/2013

01.05.2013 | Original Article

Efficacy and safety of sequential therapy versus standard triple therapy in Helicobacter pylori eradication in Kashmir India: a randomized comparative trial

verfasst von: Gul Javid, Showkat Ali Zargar, Khurshid Bhat, Bashir Ahmad Khan, Ghulam Nabi Yatoo, Ghulam Mohamad Gulzar, Altaf Hussain Shah, Jaswinder Singh Sodhi, Mushtaq Ahmad Khan, Abid Shoukat, Riyaz U Saif

Erschienen in: Indian Journal of Gastroenterology | Ausgabe 3/2013

Einloggen, um Zugang zu erhalten

Abstract

Background

Increasing resistance against Helicobacter pylori has resulted in reduced eradication rates.

Objective

This study aims to determine whether eradication rates for H. pylori infection with sequential therapy is better than standard triple therapy.

Patients

Patients with endoscopy documented peptic ulcer and H. pylori infection confirmed by histology and rapid urease test.

Intervention

Patients were randomized into two groups; 134 received standard triple therapy (pantoprazole 40 mg, clarithromycin 500 mg and amoxicillin 1 g each administered twice daily) for 10 days and 138 received sequential regimen (pantoprazole 40 mg plus amoxicillin 1 g twice daily for 5 days followed by 40 mg pantoprazole, 500 mg clarithromycin, and 500 mg tinidazole each administered twice daily for 5 days). Eradication was confirmed by histology and rapid urease test. Compliance and adverse effects were determined by the recovery of empty medicine strips and questioning.

Results

The eradication rates with sequential therapy were significantly greater than with standard therapy on both intention-to-treat analysis (76.0 % vs. 61.9 %, p = 0.005; difference, 14.1 % [95 % CI, 6.5–19 %] and per protocol analysis (84.6 % vs. 67.4 %, p = 0.002; difference, 17.2 % [95 % CI, 8.5–23.5 %]). The incidence of side effects did not differ between the two therapy groups. One patient in standard therapy discontinued treatment due to side effects.

Limitation

Cultures were not performed. Loss to follow up was 5.2 % in standard therapy and 6.5 % in sequential therapy.

Conclusion

Sequential therapy was significantly more effective than standard therapy for eradicating H. pylori infection in peptic ulcer disease in Asian patients. Side effects were similar.
Literatur
1.
Zurück zum Zitat Graham DY, Adam E, Reddy GT, et al. Sero epidemiology of Helicobacter pylori infection in India. Comparison of developing and developed countries. Dig Dis Sci. 1991;36:1084–8.PubMedCrossRef Graham DY, Adam E, Reddy GT, et al. Sero epidemiology of Helicobacter pylori infection in India. Comparison of developing and developed countries. Dig Dis Sci. 1991;36:1084–8.PubMedCrossRef
2.
Zurück zum Zitat Graham DY, Yamaoka Y. Ethical considerations of comparing sequential and traditional anti-Helicobacter therapy. Ann Intern Med. 2007;147:434–5.PubMedCrossRef Graham DY, Yamaoka Y. Ethical considerations of comparing sequential and traditional anti-Helicobacter therapy. Ann Intern Med. 2007;147:434–5.PubMedCrossRef
3.
4.
Zurück zum Zitat Laheij RJ, Rossum LG, Jansen JB, Straatman H, Verbeek AL. Evaluation of treatment regimens to cure Helicobacter pylori infection a meta-analysis. Aliment Pharmacol Ther. 1999;13:857–64.PubMedCrossRef Laheij RJ, Rossum LG, Jansen JB, Straatman H, Verbeek AL. Evaluation of treatment regimens to cure Helicobacter pylori infection a meta-analysis. Aliment Pharmacol Ther. 1999;13:857–64.PubMedCrossRef
5.
Zurück zum Zitat Perri F, Villani MR, Festa V, Quitadamo M, Andriulli A. Predictors of failure of Helicobacter pylori eradication with the standard ‘Maastricht triple therapy’. Aliment Pharmacol Ther. 2001;15:1023–9.PubMedCrossRef Perri F, Villani MR, Festa V, Quitadamo M, Andriulli A. Predictors of failure of Helicobacter pylori eradication with the standard ‘Maastricht triple therapy’. Aliment Pharmacol Ther. 2001;15:1023–9.PubMedCrossRef
6.
Zurück zum Zitat Bigard MA, Delchier JC, Riachi G, Thiabult P, Barthelemy P. One-week triple therapy using omeprazole, amoxicillin and clarithromycin for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia: influence of dosage of Omeprazole and clarithromycin. Aliment Pharmacol Ther. 1998;12:383–8.PubMedCrossRef Bigard MA, Delchier JC, Riachi G, Thiabult P, Barthelemy P. One-week triple therapy using omeprazole, amoxicillin and clarithromycin for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia: influence of dosage of Omeprazole and clarithromycin. Aliment Pharmacol Ther. 1998;12:383–8.PubMedCrossRef
7.
Zurück zum Zitat Calvet X, Ducons J, Guardiola J, et al. One-week triple versus quadruple therapy for Helicobacter pylori infection—a randomized trial. Aliment Pharmacol Ther. 2002;16:1261–7.PubMedCrossRef Calvet X, Ducons J, Guardiola J, et al. One-week triple versus quadruple therapy for Helicobacter pylori infection—a randomized trial. Aliment Pharmacol Ther. 2002;16:1261–7.PubMedCrossRef
8.
Zurück zum Zitat Deltenre M, Jonas C, van Gossum M, Buset M, Otero J, De Koster E. Omeprazole based antimicrobial therapies: results in 198 Helicobacter pylori-positive patients. Eur J Gastroenterol Hepatol. 1995;7 suppl 1:S39–44.PubMed Deltenre M, Jonas C, van Gossum M, Buset M, Otero J, De Koster E. Omeprazole based antimicrobial therapies: results in 198 Helicobacter pylori-positive patients. Eur J Gastroenterol Hepatol. 1995;7 suppl 1:S39–44.PubMed
9.
Zurück zum Zitat Vakil N. Helicobacter pylori eradication: sequential and traditional therapy. Gastroenterol Hepatol. 2009;3:59–64. Vakil N. Helicobacter pylori eradication: sequential and traditional therapy. Gastroenterol Hepatol. 2009;3:59–64.
10.
Zurück zum Zitat Ramakrishan BS. Helicobacter pylori infection in India: the case against eradication. Indian J Gastroenterol. 2006;25:25–7. Ramakrishan BS. Helicobacter pylori infection in India: the case against eradication. Indian J Gastroenterol. 2006;25:25–7.
11.
Zurück zum Zitat Thyagarajan SP, Ray P, Das BK, et al. Geographical difference in antimicrobial resistance pattern of Helicobacter pylori clinical isolates from Indian patients: multicenteric study. J Gastroenterol Hepatol. 2003;18:1373–8.PubMedCrossRef Thyagarajan SP, Ray P, Das BK, et al. Geographical difference in antimicrobial resistance pattern of Helicobacter pylori clinical isolates from Indian patients: multicenteric study. J Gastroenterol Hepatol. 2003;18:1373–8.PubMedCrossRef
12.
Zurück zum Zitat Datta S, Chattopadhyay S, Patra R, et al. Most Helicobacter pylori strains of Kolkata in India are resistant to metronidazole but susceptible to other drugs commonly used for eradication and ulcer therapy. Aliment Pharmacol Ther. 2005;22:51–7.PubMedCrossRef Datta S, Chattopadhyay S, Patra R, et al. Most Helicobacter pylori strains of Kolkata in India are resistant to metronidazole but susceptible to other drugs commonly used for eradication and ulcer therapy. Aliment Pharmacol Ther. 2005;22:51–7.PubMedCrossRef
13.
Zurück zum Zitat Fuccio L, Minardi ME, Zagari RM, Grilli D, Magrini N, Bazzoli F. Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication. Ann Intern Med. 2007;147:553–62.PubMedCrossRef Fuccio L, Minardi ME, Zagari RM, Grilli D, Magrini N, Bazzoli F. Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication. Ann Intern Med. 2007;147:553–62.PubMedCrossRef
14.
Zurück zum Zitat Zullo A, De Francesco V, Hassan C, Morini S, Vaira D. The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis. Gut. 2007;56:1353–7.PubMedCrossRef Zullo A, De Francesco V, Hassan C, Morini S, Vaira D. The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis. Gut. 2007;56:1353–7.PubMedCrossRef
15.
Zurück zum Zitat Zullo A, Hassan C, Morini S, et al. Sequential therapy for H. pylori an ‘aberrant’ therapy for general use. Dig Liver Dis. 2004;36:852–3.PubMedCrossRef Zullo A, Hassan C, Morini S, et al. Sequential therapy for H. pylori an ‘aberrant’ therapy for general use. Dig Liver Dis. 2004;36:852–3.PubMedCrossRef
16.
Zurück zum Zitat Vaira D, Zullo A, Vakil N, et al. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication. A randomized trial. Ann Intern Med. 2007;146:556–63.PubMedCrossRef Vaira D, Zullo A, Vakil N, et al. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication. A randomized trial. Ann Intern Med. 2007;146:556–63.PubMedCrossRef
17.
Zurück zum Zitat De Francesco V, Zullo A, Margiotta M, et al. Sequential treatment for Helicobacter pylori does not share the risk factors of triple therapy failure. Aliment Pharmacol Ther. 2004;19:407–14.PubMedCrossRef De Francesco V, Zullo A, Margiotta M, et al. Sequential treatment for Helicobacter pylori does not share the risk factors of triple therapy failure. Aliment Pharmacol Ther. 2004;19:407–14.PubMedCrossRef
18.
Zurück zum Zitat Zullo A, Rinaldi V, Winn S, et al. A new highly effective short-term therapy schedule for Helicobacter pylori eradication. Aliment Pharmacol Ther. 2000;14:715–8.PubMedCrossRef Zullo A, Rinaldi V, Winn S, et al. A new highly effective short-term therapy schedule for Helicobacter pylori eradication. Aliment Pharmacol Ther. 2000;14:715–8.PubMedCrossRef
19.
Zurück zum Zitat De Francesco V, Zullo A, Hassan C, et al. Two new treatment regimens for Helicobacter pylori eradication: a randomized study. Dig Liver Dis. 2001;33:676–9.PubMedCrossRef De Francesco V, Zullo A, Hassan C, et al. Two new treatment regimens for Helicobacter pylori eradication: a randomized study. Dig Liver Dis. 2001;33:676–9.PubMedCrossRef
20.
Zurück zum Zitat Newcombe RG, Altman DG. Proportion and their differences. In: Altman DG, Machin D, Trevor NB, Newcombe RG (eds). Statistics with Confidences, 2nd ed. London: BMJ Books; 2000. pp 45–56. Newcombe RG, Altman DG. Proportion and their differences. In: Altman DG, Machin D, Trevor NB, Newcombe RG (eds). Statistics with Confidences, 2nd ed. London: BMJ Books; 2000. pp 45–56.
21.
Zurück zum Zitat Kim YS, Kim SJ, Yoon JH, et al. Randomised clinical trial: the efficacy of a 10-day sequential therapy vs. a 14-day standard proton pump inhibitor-based triple therapy for Helicobacter pylori in Korea. Aliment Pharmacol Ther. 2011;34:1098–105.PubMedCrossRef Kim YS, Kim SJ, Yoon JH, et al. Randomised clinical trial: the efficacy of a 10-day sequential therapy vs. a 14-day standard proton pump inhibitor-based triple therapy for Helicobacter pylori in Korea. Aliment Pharmacol Ther. 2011;34:1098–105.PubMedCrossRef
22.
Zurück zum Zitat Uygun A, Kadayifci A, Yesilova Z, Safali M, Ilgan S, Karaeren N. Comparison of sequential and standard triple-drug regimen for Helicobacter pylori eradication: a 14-day, open-label, randomized, prospective, parallel-arm study in adult patients with nonulcer dyspepsia. Clin Ther. 2008;30:528–34.PubMedCrossRef Uygun A, Kadayifci A, Yesilova Z, Safali M, Ilgan S, Karaeren N. Comparison of sequential and standard triple-drug regimen for Helicobacter pylori eradication: a 14-day, open-label, randomized, prospective, parallel-arm study in adult patients with nonulcer dyspepsia. Clin Ther. 2008;30:528–34.PubMedCrossRef
23.
Zurück zum Zitat Park HG, Jung MK, Jung JT, et al. Randomised clinical trial: a comparative study of 10-day sequential therapy with 7-day standard triple therapy for Helicobacter pylori infection in naïve patients. Aliment Pharmacol Ther. 2012;35:56–65.PubMedCrossRef Park HG, Jung MK, Jung JT, et al. Randomised clinical trial: a comparative study of 10-day sequential therapy with 7-day standard triple therapy for Helicobacter pylori infection in naïve patients. Aliment Pharmacol Ther. 2012;35:56–65.PubMedCrossRef
24.
Zurück zum Zitat Laine L, Fennerty MB, Osato M, et al. Esomeprazole based Helicobacter pylori eradication therapy and the effect of antibiotic resistance: results of three US multicenter, double-blind trials. Am J Gastroenterol. 2000;95:3393–8.PubMedCrossRef Laine L, Fennerty MB, Osato M, et al. Esomeprazole based Helicobacter pylori eradication therapy and the effect of antibiotic resistance: results of three US multicenter, double-blind trials. Am J Gastroenterol. 2000;95:3393–8.PubMedCrossRef
25.
Zurück zum Zitat Vakil N, Lanza F, Schwartz H, Barth J. Seven-day therapy for Helicobacter pylori in the United States. Aliment Pharmacol Ther. 2004;20:99–107.PubMedCrossRef Vakil N, Lanza F, Schwartz H, Barth J. Seven-day therapy for Helicobacter pylori in the United States. Aliment Pharmacol Ther. 2004;20:99–107.PubMedCrossRef
26.
Zurück zum Zitat Greenberg ER, Anderson GL, Morgan DR, et al. 14-Day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. Lancet. 2011;378:507–14.PubMedCrossRef Greenberg ER, Anderson GL, Morgan DR, et al. 14-Day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. Lancet. 2011;378:507–14.PubMedCrossRef
27.
Zurück zum Zitat Duck WM, Sobel J, Pruckler JM, et al. Antimicrobial resistance incidence and risk factors among Helicobacter pylori-infected persons. United States Emerg Infect Dis. 2004;10:1088–94.CrossRef Duck WM, Sobel J, Pruckler JM, et al. Antimicrobial resistance incidence and risk factors among Helicobacter pylori-infected persons. United States Emerg Infect Dis. 2004;10:1088–94.CrossRef
28.
Zurück zum Zitat Thyagarajan SP, Ray P, Das BK, et al. Geographical difference in antimicrobial resistance pattern of Helicobacter pylori clinical isolates from Indian patients: multicentric study. J Gastroenterol Hepatol. 2003;18:1373–8.PubMedCrossRef Thyagarajan SP, Ray P, Das BK, et al. Geographical difference in antimicrobial resistance pattern of Helicobacter pylori clinical isolates from Indian patients: multicentric study. J Gastroenterol Hepatol. 2003;18:1373–8.PubMedCrossRef
29.
Zurück zum Zitat Bhatia V, Ahuja V, Das B, Bal C, Sharma MP. Use of imidazole-based eradication regimens for Helicobacter pylori should be abandoned in North India regardless of in vitro antibiotic sensitivity. J Gastroenterol Hepatol. 2004;19:619–25.PubMedCrossRef Bhatia V, Ahuja V, Das B, Bal C, Sharma MP. Use of imidazole-based eradication regimens for Helicobacter pylori should be abandoned in North India regardless of in vitro antibiotic sensitivity. J Gastroenterol Hepatol. 2004;19:619–25.PubMedCrossRef
30.
Zurück zum Zitat De Francesco V, Margiotta M, Zullo A, et al. Clarithromycin-resistant genotypes and eradication of Helicobacter pylori. Ann Intern Med. 2006;144:94–100.PubMedCrossRef De Francesco V, Margiotta M, Zullo A, et al. Clarithromycin-resistant genotypes and eradication of Helicobacter pylori. Ann Intern Med. 2006;144:94–100.PubMedCrossRef
31.
Zurück zum Zitat Castro Fernández M, Sánchez Muñoz D, García Díaz E, Galán Jurado MV, Rodríguez AC. Diagnosis of Helicobacter pylori infection using urease rapid test in patients with bleeding duodenal ulcer: influence of endoscopic signs and simultaneous corporal and antral biopsies. Rev Esp Enferm Dig. 2004;96:599–602.PubMed Castro Fernández M, Sánchez Muñoz D, García Díaz E, Galán Jurado MV, Rodríguez AC. Diagnosis of Helicobacter pylori infection using urease rapid test in patients with bleeding duodenal ulcer: influence of endoscopic signs and simultaneous corporal and antral biopsies. Rev Esp Enferm Dig. 2004;96:599–602.PubMed
32.
Zurück zum Zitat Archimandritis A, Tzivras M, Sougioultzis S, et al. Rapid urease test is less sensitive than histology in diagnosing Helicobacter pylori infection in patients with non-variceal upper gastrointestinal bleeding. J Gastroenterol Hepatol. 2000;15:369–73.PubMedCrossRef Archimandritis A, Tzivras M, Sougioultzis S, et al. Rapid urease test is less sensitive than histology in diagnosing Helicobacter pylori infection in patients with non-variceal upper gastrointestinal bleeding. J Gastroenterol Hepatol. 2000;15:369–73.PubMedCrossRef
Metadaten
Titel
Efficacy and safety of sequential therapy versus standard triple therapy in Helicobacter pylori eradication in Kashmir India: a randomized comparative trial
verfasst von
Gul Javid
Showkat Ali Zargar
Khurshid Bhat
Bashir Ahmad Khan
Ghulam Nabi Yatoo
Ghulam Mohamad Gulzar
Altaf Hussain Shah
Jaswinder Singh Sodhi
Mushtaq Ahmad Khan
Abid Shoukat
Riyaz U Saif
Publikationsdatum
01.05.2013
Verlag
Springer-Verlag
Erschienen in
Indian Journal of Gastroenterology / Ausgabe 3/2013
Print ISSN: 0254-8860
Elektronische ISSN: 0975-0711
DOI
https://doi.org/10.1007/s12664-013-0304-7

Weitere Artikel der Ausgabe 3/2013

Indian Journal of Gastroenterology 3/2013 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Chronische Verstopfung: „Versuchen Sie es mit grünen Kiwis!“

22.05.2024 Obstipation Nachrichten

Bei chronischer Verstopfung wirken Kiwis offenbar besser als Flohsamenschalen. Das zeigen die Daten aus einer randomisierten Studie, die der Gastroenterologe Oliver Pech beim Praxis-Update vorstellte.

So häufig greift rheumatoide Arthritis auf Organe über

21.05.2024 Rheumatoide Arthritis Nachrichten

Im Verlauf von rheumatoider Arthritis entwickeln viele Patienten extraartikuläre Manifestationen. Schwedische Forscher haben sich mit der Inzidenz und den Risikofaktoren befasst.

Blutdrucksenkung könnte Uterusmyome verhindern

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.